Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688375 | 0.89 | KDM4E (0.50) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL1285707 | 0.88 | KDM4E (0.55) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL1643365 | 0.86 | KDM4E (0.53) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL10272097 | 0.84 | SIRT2 (0.52) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL1284679 | 0.84 | ALDH1A1 (0.53) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL1688404 | 0.77 | HSD17B10 (0.60) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL14378324 | 0.76 | ALDH1A1 (0.60) | ALDH1A1KDM4EHSD17B10HPGDL3MBTL1 | |
| SCHEMBL1688393 | 0.72 | TLR7 (0.54) | ALDH1A1KDM4EHPGDL3MBTL1NPSR1 | |
| SCHEMBL6132378 | 0.70 | ALDH1A1 (0.62) | ALDH1A1HPGDTSHRL3MBTL1NPSR1 | |
| SCHEMBL6132380 | 0.70 | ALDH1A1 (0.62) | ALDH1A1HPGDTSHRL3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | ALDH1A1 1265/4885KDM4E 4075/4885HSD17B10 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.